Taro Pharmaceutical Industries Ltd. (TARO)
Jun 24, 2024 - TAR was delisted (reason: acquired by Sun Pharma)
42.97
0.00 (0.00%)
Inactive · Last trade price on Jun 21, 2024

TARO Cash Flow Statement

Millions USD. Fiscal year is Apr - Mar.
Year Ending
TTM Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 2019 - 2015
Net Income
53.8753.8725.4558.27-386.65244.24
Upgrade
Depreciation & Amortization
31.0931.0932.1325.9223.6821.38
Upgrade
Other Operating Activities
39.5939.59-25.82-242.88408.745.98
Upgrade
Operating Cash Flow
124.56124.5631.75-158.745.77271.61
Upgrade
Operating Cash Flow Growth
292.30%292.30%---83.15%-16.10%
Upgrade
Capital Expenditures
-53.97-53.97-17.55-11.8-16.99-26.63
Upgrade
Acquisitions
---1.98-91.870.010.02
Upgrade
Change in Investments
138.56138.56-107.71-66.6784.89-269.77
Upgrade
Other Investing Activities
-0.25-0.251.68-0.24-0.16-1.78
Upgrade
Investing Cash Flow
84.3484.34-125.56-170.5867.74-298.16
Upgrade
Share Issuance / Repurchase
--0-24.93-24.2-26.98
Upgrade
Financing Cash Flow
000-24.93-24.2-26.98
Upgrade
Exchange Rate Effect
-0.48-0.48-2.830.172.51-0.56
Upgrade
Net Cash Flow
208.42208.42-96.64-354.0491.82-54.1
Upgrade
Free Cash Flow
70.5870.5814.2-170.528.78244.97
Upgrade
Free Cash Flow Growth
397.18%397.18%---88.25%-17.43%
Upgrade
Free Cash Flow Margin
11.22%11.22%2.48%-30.37%5.24%37.99%
Upgrade
Free Cash Flow Per Share
1.881.880.38-4.530.756.37
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).